BACK

Gwendolyn Melnyk

Gwendolyn Melnyk

Vice President

New York Office  |  gwen.melnyk@torreya.com   |   212.257.6039

Gwendolyn Melnyk, a Vice President at Torreya, specializes in North American strategic transactions.

Before joining Torreya in 2017, Gwen was an Associate in healthcare investment banking for Jefferies LLC working on sell- and buy-side M&A deals and debt and equity financings. Prior to Jefferies, she worked as a Research Associate for Regeneron Pharmaceuticals, Inc. and earlier as a Research and Development Associate for Cytimmune Sciences, Inc.

Gwen earned a B.A. in chemical and biomolecular engineering and an M.A. in biotechnology from John Hopkins University. She also earned an M.B.A. in finance and management from New York University.

Selected Transactions

BioCentriq
Sale to
Green Cross
$73 million
May 2022
LaNova
Licensing of LM-302 to
Turning Point
Up to $1.2 billion in milestones + royalties ($25 million upfront)
May 2022
Acerus
Acquisition of Serenity LLC and global rights to Noctiva™
Serenity Pharma LLC
$41 million + milestones and royalties
March 2022
DRL
Sale of E7777 to
Citius
$40 million upfront + $76mm milestones
September 2021
Noria/PSMA
Sale to
Bayer
June 2021
Rockwell Medical
Exclusive license agreement to commercialize Triferic® in South Korea with
Jeil Pharmaceutical
September 2020
PDL
Sale of Noden to
Stanley Capital
Up to $52.83 Million
September 2020
Novaliq
License of NOV03
in North America to
Bausch Health
December 2019
Kineta
Research collaboration and license agreement for
RIG-I pathway with
Pfizer
Up to $505 million
December 2018